Literature DB >> 15970687

AKT activation and response to interferon-beta in human cancer cells.

Hanqin Lei1, Patrick J Furlong, Jin Hee Ra, Daniel Mullins, Robert Cantor, Douglas L Fraker, Francis R Spitz.   

Abstract

Significant growth inhibition and induction of apoptosis by IFN-beta in cancer cells including colorectal cancer cells have been observed. We and others have previously reported the Stat 1 induction of TRAIL is a crucial step in the IFN-beta induced apoptosis pathway. However, when evaluating the sensitivity of a panel of colorectal cancer cell lines, we found no clear correlation between activation of the Jak/Stat signaling pathway and response to interferon. In the present study, we have evaluated the interaction of the PI3k/Akt pathway and IFN-beta induced apoptosis in human colorectal cancer cells. The results demonstrate a correlation between Akt activity, phosphorylation of Bad and resistance to interferon-induced apoptosis in these cells. The association of activation of Akt, phosphorylation of Bad and resistance to IFN-beta-induced apoptosis was further supported by the observation that disruption of the pathway in a more resistant cell line led to sensitization, and expression of an activated Akt in a more sensitive cell line led to increased resistance. Taken together, this data indicates that the PI3/Akt kinase pathway may be an important contributor to IFN-beta sensitivity and resistance in colorectal cancer cells. This data demonstrates a potential pathway by which cells may develop resistance to IFN, and further elucidation of this process may allow us to better target IFN therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970687     DOI: 10.4161/cbt.4.7.1767

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

Review 1.  Interferons as inducers of apoptosis in malignant cells.

Authors:  Kevin P Kotredes; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

2.  Mechanisms of resistance to interferon-gamma-mediated cell growth arrest in human oral squamous carcinoma cells.

Authors:  Miki Hiroi; Kazumasa Mori; Keisuke Sekine; Yoshiichi Sakaeda; Jun Shimada; Yoshihiro Ohmori
Journal:  J Biol Chem       Date:  2009-07-13       Impact factor: 5.157

3.  Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS.

Authors:  Lang-Ming Chi; Chien-Wei Lee; Kai-Ping Chang; Sheng-Po Hao; Hang-Mao Lee; Ying Liang; Chuen Hsueh; Chia-Jung Yu; I-Neng Lee; Yin-Ju Chang; Shih-Ying Lee; Yuan-Ming Yeh; Yu-Sun Chang; Kun-Yi Chien; Jau-Song Yu
Journal:  Mol Cell Proteomics       Date:  2009-03-18       Impact factor: 5.911

4.  Role of the Akt pathway in mRNA translation of interferon-stimulated genes.

Authors:  Surinder Kaur; Antonella Sassano; Blazej Dolniak; Sonali Joshi; Beata Majchrzak-Kita; Darren P Baker; Nissim Hay; Eleanor N Fish; Leonidas C Platanias
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-13       Impact factor: 11.205

Review 5.  Role of Type I and II Interferons in Colorectal Cancer and Melanoma.

Authors:  Simone Di Franco; Alice Turdo; Matilde Todaro; Giorgio Stassi
Journal:  Front Immunol       Date:  2017-07-26       Impact factor: 7.561

6.  Upregulation of PITX2 Promotes Letrozole Resistance Via Transcriptional Activation of IFITM1 Signaling in Breast Cancer Cells.

Authors:  Ying-Ying Xu; Hai-Ru Yu; Jia-Yi Sun; Zhao Zhao; Shuang Li; Xin-Feng Zhang; Zhi-Xuan Liao; Ming-Ke Cui; Juan Li; Chan Li; Qiang Zhang
Journal:  Cancer Res Treat       Date:  2018-07-18       Impact factor: 4.679

7.  A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement.

Authors:  Adriana G Quiroz-Reyes; Carlos A González-Villarreal; Herminia Martínez-Rodriguez; Salvador Said-Fernández; Mario César Salinas-Carmona; Alberto Y Limón-Flores; Adolfo Soto-Domínguez; Gerardo Padilla-Rivas; Roberto Montes De Oca-Luna; Jose F Islas; Elsa N Garza-Treviño
Journal:  Mol Med Rep       Date:  2022-04-29       Impact factor: 3.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.